While CD4 is the primary receptor for IL-16, certain cells can respond to IL-16 through alternative receptors like CD9, for example, mastocytes or lung cancer cells [32], as well as via CD4- and CD9-independent mechanisms [33]. Here, CD9 is linked to lung carcinoma.